Aurobindo Ranitidine Capsules 150 mg, 500 count bottle, Rx Only Distributed by: Aurobindo Pharma ...
FDA Drug Recall #D-0530-2020 — Class II — November 6, 2019
Recall Summary
| Recall Number | D-0530-2020 |
| Classification | Class II — Moderate risk |
| Date Initiated | November 6, 2019 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | AuroMedics Pharma LLC |
| Location | East Windsor, NJ |
| Product Type | Drugs |
| Quantity | 26,736 bottles |
Product Description
Aurobindo Ranitidine Capsules 150 mg, 500 count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 NDC 59651-144-05
Reason for Recall
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.
Distribution Pattern
nationwide
Lot / Code Information
RA1518002-B Jul 2020 RA1518003-A Jul 2020 RA1518004-A Aug 2020 RA1518005-A Aug 2020 RA1518007-A Sep 2020 RA1518008-A Sep 2020 RA1518009-A Sep 2020 RA1518010-A Oct 2020 RA1518011-A Nov 2020 RA1518012-A Nov 2020 RA1518013-A Nov 2020 RA1518014-A Nov 2020 RA1518015-A Nov 2020 RA1519003-B May 2021 RA1519004-A May 2021
Other Recalls from AuroMedics Pharma LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0020-2023 | Class II | Fondaparinux Sodium Injection, USP, 7.5 mg per ... | Sep 30, 2022 |
| D-0013-2023 | Class II | Acyclovir Sodium Injection, 500mg/10mL (50mg/mL... | Sep 26, 2022 |
| D-1551-2022 | Class III | Tranexamic Acid Injection, USP, 1000mg per 10 m... | Sep 26, 2022 |
| D-0556-2022 | Class I | Polymyxin B for Injection USP, 500,000 Units pe... | Jan 26, 2022 |
| D-0248-2021 | Class II | Acetaminophen Injection 1,000 mg per 100 mL (10... | Dec 30, 2020 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.